News >

FDA Approves Adjuvant Pembrolizumab in Stage III Melanoma

Gina Columbus @ginacolumbusonc
Published: Tuesday, Feb 19, 2019

The FDA has approved the PD-1 inhibitor pembrolizumab (Keytruda) for the adjuvant treatment of patients with high-risk stage III melanoma with lymph node involvement following complete resection.This is the first anti–PD-1 therapy evaluated in the adjuvant setting across patients with stage IIIA, stage IIIB, and stage IIIC melanoma.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication